Review
Allergy
Claudia Hulpusch, Andreas B. Weins, Claudia Traidl-Hoffmann, Matthias Reiger
Summary: Atopic eczema is an inflammatory skin disease influenced by genetic, immunological, and environmental factors. It is characterized by skin barrier disruption, abnormal immune response, and the impact of external factors. Prevention and appropriate treatment are crucial, and while new therapeutic options have emerged, individualized precision medicine approaches are still necessary.
Article
Allergy
Jacob W. Glickman, Celina Dubin, Dante Dahabreh, Joseph Han, Ester Del Duca, Yeriel D. Estrada, Ning Zhang, Grace W. Kimmel, Giselle Singer, James G. Krueger, Ana B. Pavel, Emma Guttman-Yassky
Summary: This study analyzed scalp and serum from patients with moderate-to-severe alopecia areata, revealing differential expression of inflammatory genes in affected scalp tissue closely correlated with clinical disease severity. Integrative analysis of scalp and serum biomarkers demonstrated the systemic nature of the disease.
Article
Allergy
Anne-Sofie Halling, Maria Rasmussen Rinnov, Iben Frier Ruge, Trine Gerner, Nina Haarup Ravn, Mette Hjorslev Knudgaard, Simon Trautner, Nikolai Loft, Lone Skov, Simon F. Thomsen, Alexander Egeberg, Emma Guttman-Yassky, Aske L. L. Rosted, Troels Petersen, Ivone Jakasa, Sanja Kezic, Jacob P. Thyssen
Summary: This study aimed to investigate whether skin biomarkers collected in infancy can predict the onset of atopic dermatitis (AD) and be used in future prevention trials. The results showed that skin biomarkers collected at birth did not predict the onset of AD. However, elevated levels of certain immune and barrier biomarkers collected at 2 months of age increased the risk of AD.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Jackeline Franco, Bartek Rajwa, Paulo Gomes, Harm HogenEsch
Summary: The study found significant differences in the lipid composition of skin and blood between dogs with atopic dermatitis and controls, with treatments impacting both skin and blood lipids. A set of skin lipid features accurately classified samples as control or atopic dermatitis with 95% accuracy. Blood lipids discriminated between control and atopic dogs with 90% accuracy, supporting the use of rapid lipid profiling as a tool for identifying novel biomarkers.
Review
Immunology
Paola Facheris, Jane Jeffery, Ester Del Duca, Emma Guttman-Yassky
Summary: Atopic dermatitis (AD) is a complex and heterogeneous inflammatory skin disease. Different phenotypes of AD based on patient characteristics have been defined, emphasizing the need for personalized treatment. Advances in understanding AD pathogenesis have led to an expansion in therapeutic options. Biomarkers in clinical studies are helping to clarify the role of cytokines and immune pathways in AD and enable personalized medicine. This review discusses changes in the understanding and treatment of AD, highlighting the scientific rationale behind targeted treatments and presenting recent clinical efficacy data.
CELLULAR & MOLECULAR IMMUNOLOGY
(2023)
Article
Dermatology
Jesper Gronlund Holm, Guillem Hurault, Tove Agner, Maja Lisa Clausen, Sanja Kezic, Reiko J. Tanaka, Simon Francis Thomsen
Summary: The study found that specific immunoinflammatory biomarkers in the serum, mainly of the Th2 pathway, are correlated with disease severity in patients with AD. Predictive models identified biomarkers associated with disease severity but this finding warrants further investigation.
Review
Biochemistry & Molecular Biology
Misa Itamura, Yu Sawada
Summary: The skin, as a peripheral lymphoid organ, acts as a crucial defense mechanism against external environmental stimuli. However, prolonged exposure to these factors leads to chronic inflammation and eventually triggers systemic organ inflammation. Atopic dermatitis (AD) is a chronic inflammatory skin disease influenced by environmental factors, such as dry conditions, chemical exposure, and microorganisms. The pathogenesis of AD involves various cytokines, which have recently been found to influence systemic organ function and oncogenesis. This review focuses on the impact of AD on the development of systemic inflammatory diseases and malignancies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Dermatology
A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, G. Avila Valle, S. Barbarot, T. Bieber, H. A. Brough, P. Calzavara Pinton, S. Christen-Zach, M. Deleuran, M. Dittmann, C. Dressler, A. H. Fink-Wagner, N. Fosse, K. Gaspar, L. Gerbens, U. Gieler, G. Girolomoni, S. Gregoriou, C. G. Mortz, A. Nast, U. Nygaard, M. Redding, E. M. Rehbinder, J. Ring, M. Rossi, E. Serra-Baldrich, D. Simon, Z. Z. Szalai, J. C. Szepietowski, A. Torrelo, T. Werfel, C. Flohr
Summary: The evidence- and consensus-based guideline on atopic eczema, developed according to the EuroGuiDerm Guideline and Consensus Statement Development Manual, involves the participation of 29 experts from 12 European countries. The first part of the guideline provides general information, guidance, and detailed information on systemic treatment options, including conventional immunosuppressive drugs, biologics, and janus kinase inhibitors. The second part will cover other aspects of treatment.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Minkyoung Sung, Soo-Eun Sung, Kyung-Ku Kang, Joo-Hee Choi, Sijoon Lee, KilSoo Kim, Ju-Hyeon Lim, Gun Woo Lee, Hyo-Deog Rim, Seunghee Won, Byung-Soo Kim, Kyungmin Kim, Seoyoung Jang, Sang Gyu Kwak, Jungmin Woo, Min-Soo Seo
Summary: Atopic dermatitis (AD) is a chronic allergic inflammatory skin disease characterized by symptoms like eczema and itching. Psychological stress can trigger neuroinflammation in the brain in AD patients, leading to changes in microRNAs (miRNAs) in neuronal exosomes (nEVs). This study found that certain miRNAs in nEVs may serve as stress-related biomarkers associated with AD and stress-induced depression.
Review
Pharmacology & Pharmacy
Pier Giorgio Puzzovio, Francesca Levi-Schaffer
Summary: The understanding of the pathologic mechanisms of asthma and atopic dermatitis has improved in recent years. However, the high heterogeneity of both diseases complicates diagnosis and treatment, with current strategies mainly focusing on symptom control rather than full healing. There is a need for more personalized approaches to improve diagnosis and treatment efficacy.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Allergy
Doreen Siegels, Annice Heratizadeh, Susanne Abraham, Jonas Binnmyr, Knut Brockow, Alan D. Irvine, Susanne Halken, Charlotte G. Mortz, Carsten Flohr, Peter Schmid-Grendelmeier, Lauri-Ann Van der Poel, Antonella Muraro, Stephan Weidinger, Thomas Werfel, Jochen Schmitt
Summary: This study critically evaluated systemic treatments for moderate-to-severe AD, with the most reliable and safe trial evidence found for the use of dupilumab in adults for up to 1 year. Limited evidence-based conclusions were drawn for other systemic treatments due to methodological restrictions. Therefore, head-to-head trials with novel systemic treatments are needed to clarify the future role of conventional therapies.
Article
Cell & Tissue Engineering
Chunting Hua, Qichang Liang, Siji Chen, Jiang Zhu, Yi Tang, Xianzhen Chen, Yinjing Song, Stijn van der Veen, Hao Cheng
Summary: Stem cell therapy can effectively improve symptoms of atopic dermatitis by regulating abnormal immune and inflammatory status. In a mouse model, researchers found that stem cell treatment could alleviate skin and immune organ pathology and provided gene expression signatures that may help with clinical diagnosis and personalized treatment.
STEM CELL RESEARCH & THERAPY
(2023)
Article
Allergy
Robert Bissonnette, Janet Dubois, Paola Facheris, Ester Del Duca, Madeline Kim, Joel Correa Da Rosa, Damian L. Trujillo, Swaroop Bose, Angel D. Pagan, David Wustrow, Dirk G. Brockstedt, Brian Wong, Paul D. Kassner, Jasmina Jankicevic, William Ho, Laurence E. Cheng, Emma Guttman-Yassky
Summary: This study is the first clinical research using an oral CCR4 antagonist, demonstrating clinical improvement and modulation of the cutaneous transcriptomic profile in an inflammatory skin disease.
Article
Medicine, Research & Experimental
Yi Tang, Ma Li, Yixin Su, Yue Du, Xia Wu, Xianzhen Chen, Yinjing Song, Lihua Lai, Hao Cheng
Summary: In this study, integrated transcriptomic and metabolomic analyses were used to study the potential mechanisms of DNCB-induced AD-like skin lesions. DNCB was found to induce AD-like skin lesions in mice, and alterations in transcription and metabolism were observed. A total of 3413 differentially expressed metabolites were detected between DNCB-induced AD-like mice and healthy controls, and the expression of genes associated with metabolic pathways was significantly altered. These findings provide insights into the possible mechanism of AD and potential targets for drug development.
Article
Biochemistry & Molecular Biology
Rebecca Riedl, Annika Kuehn, Denise Rietz, Betty Hebecker, Karl-Gunther Glowalla, Lukas K. Peltner, Paul M. Jordan, Oliver Werz, Stefan Lorkowski, Cornelia Wiegand, Maria Wallert
Summary: This study established a DNCB-induced mouse model of AD with a detailed procedure description and classification of the AD human-like skin type. The model displayed various pathological changes associated with AD, such as thickening of the skin layers, altered skin barrier proteins, increased cytokine expression, and dysregulated gene expression. Additionally, increased mast cell infiltration and elevated IgE and histamine levels were observed, indicating a link to type I allergy reactions. Overall, this model mimics the features of a mild human-like extrinsic AD in murine skin.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Dermatology
Kristina Navrazhina, John W. Frew, David Grand, Samuel C. Williams, Hong Hur, Juana Gonzalez, Sandra Garcet, James G. Krueger
Summary: This study reveals that brodalumab, a human anti-IL-17 receptor A monoclonal antibody, effectively reduces inflammation and improves related pathways in Hidradenitis suppurativa (HS) patients. The response to treatment is best assessed in perilesional skin, and baseline expression levels of LCN2 and IL-17A can be used as predictive biomarkers for treatment response.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Allergy
Benjamin Ungar, Jacob W. Glickman, Alexandra K. Golant, Celina Dubin, Olga Marushchak, Alyssa Gontzes, Daniela Mikhaylov, Giselle K. Singer, Danielle Baum, Nancy Wei, Antonio Sanin, Diana Gruenstein, Mark G. Lebwohl, Ana B. Pavel, Emma Guttman-Yassky
Summary: This study aimed to investigate the hypothesis that targeting Th2 with the IL4Ra-antagonist, dupilumab, could rebalance the Th1/Th2 axis in inflammatory disease patients, potentially leading to attenuated COVID-19 symptoms.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2022)
Article
Dermatology
Merav Koschitzky, Kristina Navrazhina, Michael S. Garshick, Juana Gonzalez, Joseph Han, Sandra Garcet, James G. Krueger
Summary: This study aimed to identify biomarkers of cardiovascular (CV) risk in psoriasis blood that are reduced by ustekinumab. The results showed that 43 out of 276 proteins were down-regulated after treatment, and 8 of them were initially elevated above thresholds associated with enhanced CV risk.
EXPERIMENTAL DERMATOLOGY
(2022)
Editorial Material
Biochemistry & Molecular Biology
Thomas U. Marron, Matthew D. Galsky, Bachir Taouli, Maria Isabel Fiel, Stephen Ward, Edward Kim, David Yankelevitz, Deborah Doroshow, Emma Guttman, Benjamin Ungar, Saurabh Mehandru, Benjamin J. Golas, Daniel Labow, John Sfakianos, Sujit S. Nair, Dimple Chakravarty, Michael Buckstein, Xiaoyu Song, Effi Kenigsberg, Sacha Gnjatic, Brian D. Brown, Joseph Sparano, Ashutosh Tewari, Myron Schwartz, Nina Bhardwaj, Miriam Merad
Summary: Window-of-opportunity trials offer a platform to understand the mechanisms of short-duration pre-surgical therapies, but there is a need for a paradigm shift in trial design, specimen collection, and analysis.
Article
Oncology
Jean-Eudes Fahrner, Imran Lahmar, Anne-Gaelle Goubet, Yacine Haddad, Agathe Carrier, Marine Mazzenga, Damien Drubay, Carolina Alves Costa Silva, Eric de Sousa, Cassandra Thelemaque, Clea Melenotte, Agathe Dubuisson, Arthur Geraud, Gladys Ferrere, Roxanne Birebent, Camille Bigenwald, Marion Picard, Luigi Cerbone, Joana R. Lerias, Ariane Laparra, Alice Bernard-Tessier, Benoit Kloeckner, Marianne Gazzano, Francois-Xavier Danlos, Safae Terrisse, Eugenie Pizzato, Caroline Flament, Pierre Ly, Eric Tartour, Nadine Benhamouda, Lydia Meziani, Abdelhakim Ahmed-Belkacem, Makoto Miyara, Guy Gorochov, Fabrice Barlesi, Alexandre Trubert, Benjamin Ungar, Yeriel Estrada, Caroline Pradon, Emmanuelle Gallois, Fanny Pommeret, Emeline Colomba, Pernelle Lavaud, Marc Deloger, Nathalie Droin, Eric Deutsch, Bertrand Gachot, Jean-Philippe Spano, Mansouria Merad, Florian Scotte, Aurelien Marabelle, Frank Griscelli, Jean-Yves Blay, Jean-Charles Soria, Miriam Merad, Fabrice Andre, Juliette Villemonteix, Mathieu F. Chevalier, Sophie Caillat-Zucman, Florence Fenollar, Emma Guttman-Yassky, Odile Launay, Guido Kroemer, Bernard La Scola, Markus Maeurer, Lisa Derosa, Laurence Zitvogel
Summary: This study investigates the polarity and specificity of memory T cells against SARS-CoV-2 viral lysates and peptides to determine factors associated with protection against COVID-19. The research reveals a potential imbalance in cytokine release and a specific T cell deficit that may contribute to susceptibility to COVID-19. Current vaccines show variable efficacy in triggering immune responses, suggesting the need for next-generation vaccines to address viral variants.
Review
Pharmacology & Pharmacy
Julia Cheng, Paola Facheris, Benjamin Ungar, Emma Guttman-Yassky
Summary: Chronic hand eczema (CHE) is a burdensome condition with limited treatment options. This review discusses the pathogenesis and currently available treatments for CHE, as well as emerging drugs being studied in clinical trials. Expert opinion suggests that immunomodulatory drugs such as JAK inhibitors and Th2-targeting antibodies hold promise for CHE treatment. Future management of CHE may involve more targeted therapies through clinical trials, moving away from broad immunosuppressants with more side effects.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2022)
Article
Dermatology
Claire Q. Wang, Sokol Haxhinasto, Sandra Garcet, Norma Kunjravia, Inna Cueto, Juana Gonzalez, Darshna Rambhia, Olivier Harari, Matthew A. Sleeman, Jennifer D. Hamilton, Wei Keat Lim, Jan Freudenberg, George D. Kalliolias, Paresh Thakker, Robert Bissonnette, James G. Krueger
Summary: Palmoplantar pustular psoriasis (PPPP) and non-pustular palmoplantar psoriasis (NPPP) are localized, debilitating forms of psoriasis. This study found that NPPP shows more pronounced T helper 1-mediated inflammation, while PPPP exhibits stronger neutrophil-associated activity.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Article
Allergy
Ana B. Pavel, Ester Del Duca, Julia Cheng, Jianni Wu, Benjamin Ungar, Yeriel D. Estrada, Carolyn Jack, Catherine Maari, Etienne Saint-Cyr Proulx, Francisco Ramirez-Valle, James G. Krueger, Robert Bissonnette, Emma Guttman-Yassky
Summary: The treatment of inflammatory skin diseases needs experimental models of skin inflammation in humans to predict treatment effects. In this study, four common sensitizers were administered to healthy patients, and it was found that diphencyprone induced the strongest immune response and best modeled the barrier defects characteristic of atopic dermatitis and psoriasis.
Letter
Allergy
Benjamin Ungar, Susan Hartzell, Daniel Lozano-Ojalvo, Sabrina Ghalili, Swaroop Bose, Alexandra K. Golant, Kathryn Tan, Yeriel D. Estrada, Giselle K. Singer, Ana B. Pavel, Paolo Cravedi, Emma Guttman-Yassky
Letter
Dermatology
Shayan Owji, Helen He, Joseph Han, Peter Baek, Daniel Yassky, Nicholas Gulati, Benjamin Ungar, Jonathan Ungar
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Joseph Han, Scott Stratman, Jade N. Young, Dina Poplausky, Shayan Owji, Yen Luu, Yeriel Estrada, Joel Correa da Rosa, James G. Krueger, Nicholas Gulati
Summary: Diphencyprone (DPCP) causes a delayed-type hypersensitivity reaction when applied topically, and is used clinically for various conditions. In this study, proteomic analysis of healthy volunteers showed upregulation of immune cell activation, tissue remodeling, antineoplastic markers, and Th1 axis markers following DPCP application. Negative regulators of immune function were also upregulated, which may explain the therapeutic benefits in autoimmune conditions. The study also revealed a transient Th2 response followed by Th1 polarization. Overall, DPCP induces a complex and evolving immunological response.
JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Tu Hu, Tanja Todberg, David Adrian Ewald, Ilka Hoof, Joel Correa da Rosa, Lone Skov, Thomas Litman
Summary: The skin transcriptome of atopic dermatitis (AD) is stable over time, with the largest variation due to disease, individual, and skin site. AD-specific differentially expressed genes revealed disrupted skin barrier and activated immune response as the main features of AD. Potential novel targets in AD were also identified. This study provides new methods and insights for future skin research.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Article
Allergy
Paola Facheris, Joel Correa Da Rosa, Angel D. D. Pagan, Michael Angelov, Ester Del Duca, Grace Rabinowitz, Pedro Jesus Gomez Arias, Camille Rothenberg Lausell, Yeriel D. D. Estrada, Swaroop Bose, Mashkura Chowdhury, Avner Shemer, Ana B. B. Pavel, Emma Guttman-Yassky
Summary: The unique characteristics of adult-onset atopic dermatitis (AOAD) compared to pediatric-onset AD persisting into adulthood (POAD) have not been well-studied, hindering the development of targeted therapeutics. This study analyzed skin and blood samples from AOAD, POAD, and healthy controls and found that both AOAD and POAD showed immune and barrier dysregulations with shared Th2/Th22 hyperactivation. POAD had greater inflammation and compromised epidermal barrier compared to AOAD. AOAD also had more dysregulated proteins in serum, including pro-inflammatory and cardiovascular-risk markers.
Letter
Dermatology
Ross O'Hagan, Stella A. Caldas, Joel Correa M. da Rosa, Emma Guttman-Yassky, Benjamin Ungar
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Letter
Allergy
Benjamin Ungar, Leore Lavin, Alexandra K. Golant, Alyssa Gontzes, Eden David, Yeriel D. Estrada, Giselle K. Singer, Ana B. Pavel, Emma Guttman-Yassky
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
(2022)
